12 September 2017

Issue of Equity

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it has allotted, in aggregate, 217,475 new ordinary shares of 1p each in the Company (“Ordinary Shares”) to Orthomimetics Limited, in order to satisfy the final tranche of the deferred consideration share provisions in relation to the ChondroMimetic assets acquisition, as announced on 14 September 2015. 

Application has been made for the 217,475 new Ordinary Shares to be admitted to trading on AIM (“Admission”), which is expected to occur at 8.00 a.m. on or around 15 September 2017.  The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the FCA’s Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 324,516,552 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company

Enquiries: 

Collagen Solutions Plc
Jamal Rushdy, Chief Executive Officer
Gill Black, Chief Financial Officer
Contact via Walbrook
   
Cenkos Securities plc (Nominated Adviser and Broker)
Stephen Keys
Steve Cox
Tel: 0207 397 8900
   
Walbrook PR
Mike Wort
Anna Dunphy
Tel: 020 7933 8780 or collagen@walbrookpr.com
Mob: 07900 608 002
Mob: 07876 741 001